Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoCellular Therapeutics, a developer of immune-based therapies for the treatment of brain and other cancers, has received a US patent relating to a technology for the treatment of cancer.
Subscribe to our email newsletter
ImmunoCellular received patent no. 7,939,090, entitled ‘System and method for the treatment of cancer, including cancers of the central nervous system,’ that covers the combination of a dendritic cell based vaccine combined with a regimen of chemotherapy enhances the clinical efficacy of treatment.
ImmunoCellular Therapeutics president and CEO Manish Singh said ICT-107, the company’s dendritic cell based vaccine candidate for the treatment of glioblastoma multiforme (GBM), elicits a cytotoxic tumor reactive response that in combination with chemotherapy might alter tumors by priming their death machinery.
ImmunoCellular Therapeutics plans to expand its Phase II trial of ICT-107 which is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107 to target multiple tumor associated antigens for glioblastoma.